{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:24:33Z","timestamp":1793039073941,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP13bm0104001"],"award-info":[{"award-number":["JP13bm0104001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23bm1323001"],"award-info":[{"award-number":["JP23bm1323001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ama121050j0002"],"award-info":[{"award-number":["22ama121050j0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ek0610017h0003"],"award-info":[{"award-number":["20ek0610017h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17J40184"],"award-info":[{"award-number":["17J40184"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-024-03922-x","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T08:01:52Z","timestamp":1726732912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cell transplantation-mediated dystrophin supplementation efficacy in Duchenne muscular dystrophy mouse motor function improvement demonstrated by enhanced skeletal muscle fatigue tolerance"],"prefix":"10.1186","volume":"15","author":[{"given":"Cl\u00e9mence Kiho","family":"Bourgeois Yoshioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Takenaka-Ninagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuho","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"3922_CR1","volume-title":"Paraplegie hypertrophique de l\u2019enfance de cause cerebrale","author":"G Duchenne","year":"1861","unstructured":"Duchenne G. Paraplegie hypertrophique de l\u2019enfance de cause cerebrale. Paris: Bailliere et Fils; 1861."},{"key":"3922_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifir\u00f2 G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:141.","journal-title":"Orphanet J Rare Dis"},{"key":"3922_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","volume":"21","author":"T Markati","year":"2022","unstructured":"Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 2022;21:814\u201329.","journal-title":"Lancet Neurol"},{"key":"3922_CR4","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","volume":"394","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, B\u00f6nnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394:2025\u201338.","journal-title":"Lancet"},{"key":"3922_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREAT-NMD DMD global database: analysis of more than 7000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36:395\u2013402.","journal-title":"Hum Mutat"},{"key":"3922_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919\u201328.","journal-title":"Cell"},{"key":"3922_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/338259a0","volume":"338","author":"KP Campbell","year":"1989","unstructured":"Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature. 1989;338:259\u201362.","journal-title":"Nature"},{"key":"3922_CR8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. Compr Physiol. 2015;5:1223\u201339.","journal-title":"Compr Physiol"},{"key":"3922_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1023\/A:1027309822007","volume":"24","author":"M Royuela","year":"2003","unstructured":"Royuela M, Chazalette D, Hugon G, Paniagua R, Guerlavais V, Fehrentz JA, et al. Formation of multiple complexes between beta-dystroglycan and dystrophin family products. J Muscle Res Cell Motil. 2003;24:387\u201397.","journal-title":"J Muscle Res Cell Motil"},{"issue":"24","key":"3922_CR10","doi-asserted-by":"publisher","first-page":"16080","DOI":"10.3390\/ijms232416080","volume":"23","author":"N Dubuisson","year":"2022","unstructured":"Dubuisson N, Versele R, Planchon C, Selvais CM, Noel L, Abou-Samra M, et al. Histological methods to assess skeletal muscle degeneration and regeneration in Duchenne muscular dystrophy. Int J Mol Sci. 2022;23(24):16080.","journal-title":"Int J Mol Sci"},{"key":"3922_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbadis.2006.05.010","volume":"1772","author":"JM Ervasti","year":"2007","unstructured":"Ervasti JM. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta. 2007;1772:108\u201317.","journal-title":"Biochim Biophys Acta"},{"key":"3922_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367.","journal-title":"Lancet Neurol"},{"key":"3922_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175675","volume":"947","author":"G Patterson","year":"2023","unstructured":"Patterson G, Conner H, Groneman M, Blavo C, Parmar MS. Duchenne muscular dystrophy: current treatment and emerging exon skipping and gene therapy approach. Eur J Pharmacol. 2023;947: 175675.","journal-title":"Eur J Pharmacol"},{"key":"3922_CR14","volume":"2016","author":"E Matthews","year":"2016","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Datab Syst Rev. 2016;2016: CD003725.","journal-title":"Cochrane Datab Syst Rev"},{"issue":"Suppl 2","key":"3922_CR15","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1542\/peds.2018-0333E","volume":"142","author":"LM Ward","year":"2018","unstructured":"Ward LM, Hadjiyannakis S, McMillan HJ, Noritz G, Weber DR. Bone health and osteoporosis management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142(Suppl 2):S34-42.","journal-title":"Pediatrics"},{"key":"3922_CR16","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1007\/s00415-023-11796-x","volume":"270","author":"M Chang","year":"2023","unstructured":"Chang M, Cai Y, Gao Z, Chen X, Liu B, Zhang C, et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J Neurol. 2023;270:3733\u201349.","journal-title":"J Neurol"},{"key":"3922_CR17","doi-asserted-by":"publisher","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","volume":"11","author":"JR Mendell","year":"2023","unstructured":"Mendell JR, Shieh PB, McDonald CM, Sahenk Z, Lehman KJ, Lowes LP, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol. 2023;11:1167762.","journal-title":"Front Cell Dev Biol"},{"key":"3922_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/JND-221656","volume":"10","author":"PR Clemens","year":"2023","unstructured":"Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, McDonald CM, et al. Efficacy and safety of viltolarsen in boys with Duchenne muscular dystrophy: results from the Phase 2, open-label, 4-year extension study. J Neuromuscul Dis. 2023;10:439\u201347.","journal-title":"J Neuromuscul Dis"},{"key":"3922_CR19","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94:e2270\u201382.","journal-title":"Neurology"},{"key":"3922_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/mus.27662","volume":"66","author":"J Iff","year":"2022","unstructured":"Iff J, Gerrits C, Zhong Y, Tuttle E, Birk E, Zheng Y, et al. Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy. Muscle Nerve. 2022;66:262\u20139.","journal-title":"Muscle Nerve"},{"key":"3922_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021;64:285\u201392.","journal-title":"Muscle Nerve"},{"key":"3922_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.nmd.2010.07.276","volume":"20","author":"S Forrest","year":"2010","unstructured":"Forrest S, Meloni PL, Muntoni F, Kim J, Fletcher S, Wilton SD. Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations. Neuromuscul Disord. 2010;20:810\u20136.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3922_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12015-023-10653-8","volume":"20","author":"A Akat","year":"2023","unstructured":"Akat A, Kara\u00f6z E. Cell therapy strategies on Duchenne muscular dystrophy: a systematic review of clinical applications. Stem Cell Rev Rep. 2023;20(1):138\u201358.","journal-title":"Stem Cell Rev Rep"},{"key":"3922_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113086","volume":"323","author":"C Sun","year":"2020","unstructured":"Sun C, Serra C, Lee G, Wagner KR. Stem cell-based therapies for Duchenne muscular dystrophy. Exp Neurol. 2020;323: 113086.","journal-title":"Exp Neurol"},{"key":"3922_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2008.05.049","volume":"134","author":"M Cerletti","year":"2008","unstructured":"Cerletti M, Jurga S, Witczak CA, Hirshman MF, Shadrach JL, Goodyear LJ, et al. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell. 2008;134:37\u201347.","journal-title":"Cell"},{"key":"3922_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.stem.2012.02.015","volume":"10","author":"R Darabi","year":"2012","unstructured":"Darabi R, Arpke RW, Irion S, Dimos JT, Grskovic M, Kyba M, et al. Human ES- and iPS-derived myogenic progenitors restore dystrophin and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell. 2012;10:610\u20139.","journal-title":"Cell Stem Cell"},{"key":"3922_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40659-020-00288-1","volume":"53","author":"R He","year":"2020","unstructured":"He R, Li H, Wang L, Li Y, Zhang Y, Chen M, et al. Engraftment of human induced pluripotent stem cell-derived myogenic progenitors restores dystrophin in mice with duchenne muscular dystrophy. Biol Res. 2020;53:22.","journal-title":"Biol Res"},{"key":"3922_CR28","doi-asserted-by":"publisher","first-page":"96ra578","DOI":"10.1126\/scitranslmed.3002342","volume":"3","author":"FS Tedesco","year":"2011","unstructured":"Tedesco FS, Hoshiya H, D\u2019Antona G, Gerli MF, Messina G, Antonini S, et al. Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy. Sci Transl Med. 2011;3:96ra578.","journal-title":"Sci Transl Med"},{"key":"3922_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.stemcr.2020.06.004","volume":"15","author":"M Zhao","year":"2020","unstructured":"Zhao M, Tazumi A, Takayama S, Takenaka-Ninagawa N, Nalbandian M, Nagai M, et al. Induced fetal human muscle stem cells with high therapeutic potential in a mouse muscular dystrophy model. Stem Cell Rep. 2020;15:80\u201394.","journal-title":"Stem Cell Rep"},{"key":"3922_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2024.100523","volume":"30","author":"N Takenaka-Ninagawa","year":"2024","unstructured":"Takenaka-Ninagawa N, Goto M, Bourgeois-Yoshioka CK, Miki M, Sakurai H. Cell therapy for duchenne muscular dystrophy using induced pluripotent stem cell-derived muscle stem cells and the potential of regenerative rehabilitation. Curr Opin Biomed Eng. 2024;30:100523.","journal-title":"Curr Opin Biomed Eng"},{"key":"3922_CR31","first-page":"399","volume":"18","author":"M Malik","year":"2022","unstructured":"Malik M, Siemionow M, Cwykiel J, Heydemann A, Garcia-Martinez J, Siemionow K, et al. Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in mdx mouse model of Duchenne muscular dystrophy. Postepy Kardiol Interwencyjnej. 2022;18:399\u2013406.","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"3922_CR32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ymthe.2018.01.021","volume":"26","author":"PS Iyer","year":"2018","unstructured":"Iyer PS, Mavoungou LO, Ronzoni F, Zemla J, Schmid-Siegert E, Antonini S, et al. Autologous cell therapy approach for Duchenne muscular dystrophy using PiggyBac transposons and mesoangioblasts. Mol Ther. 2018;26:1093\u2013108.","journal-title":"Mol Ther"},{"key":"3922_CR33","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.stemcr.2021.10.014","volume":"16","author":"N Xie","year":"2021","unstructured":"Xie N, Chu SN, Azzag K, Schultz CB, Peifer LN, Kyba M, et al. In vitro expanded skeletal myogenic progenitors from pluripotent stem cell-derived teratomas have high engraftment capacity. Stem Cell Rep. 2021;16:2900\u201312.","journal-title":"Stem Cell Rep"},{"key":"3922_CR34","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1007\/s12015-022-10384-2","volume":"18","author":"M Siemionow","year":"2022","unstructured":"Siemionow M, Langa P, Brodowska S, Kozlowska K, Zalants K, Budzynska K, et al. Long-term protective effect of human dystrophin expressing chimeric (DEC) cell therapy on amelioration of function of cardiac, respiratory and skeletal muscles in Duchenne muscular dystrophy. Stem Cell Rev Rep. 2022;18:2872\u201392.","journal-title":"Stem Cell Rev Rep"},{"key":"3922_CR35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/jnnp-2016-315106.142","volume":"87","author":"V Ricotti","year":"2016","unstructured":"Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, et al. The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry. 2016;87:149\u201355.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3922_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/gt.2011.44","volume":"18","author":"K Shiomi","year":"2011","unstructured":"Shiomi K, Kiyono T, Okamura K, Uezumi M, Goto Y, Yasumoto S, et al. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene Ther. 2011;18:857\u201366.","journal-title":"Gene Ther"},{"key":"3922_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.bbrc.2004.12.191","volume":"328","author":"H Kudoh","year":"2005","unstructured":"Kudoh H, Ikeda H, Kakitani M, Ueda A, Hayasaka M, Tomizuka K, et al. A new model mouse for Duchenne muscular dystrophy produced by 2.4-Mb deletion of dystrophin gene using Cre-loxP recombination system. Biochem Biophys Res Commun. 2005;328:507\u201316.","journal-title":"Biochem Biophys Res Commun"},{"key":"3922_CR38","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1016\/j.celrep.2019.07.078","volume":"28","author":"M Yamamoto","year":"2019","unstructured":"Yamamoto M, Kim M, Imai H, Itakura Y, Ohtsuki G. Microglia-triggered plasticity of intrinsic excitability modulates psychomotor behaviors in acute cerebellar inflammation. Cell Rep. 2019;28:2923-2938.e8.","journal-title":"Cell Rep"},{"key":"3922_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1021\/cb100313n","volume":"6","author":"M Nakano","year":"2011","unstructured":"Nakano M, Imamura H, Nagai T, Noji H. Ca2\u207a regulation of mitochondrial ATP synthesis visualized at the single cell level. ACS Chem Biol. 2011;6:709\u201315.","journal-title":"ACS Chem Biol"},{"key":"3922_CR40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/mus.25218","volume":"55","author":"Y Itoh","year":"2017","unstructured":"Itoh Y, Murakami T, Mori T, Agata N, Kimura N, Inoue-Miyazu M, et al. Training at non-damaging intensities facilitates recovery from muscle atrophy. Muscle Nerve. 2017;55:243\u201353.","journal-title":"Muscle Nerve"},{"key":"3922_CR41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/jb\/118.5.959","volume":"118","author":"R Matsuda","year":"1995","unstructured":"Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem. 1995;118:959\u201364.","journal-title":"J Biochem"},{"key":"3922_CR42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s42003-023-04663-y","volume":"6","author":"J Choi","year":"2023","unstructured":"Choi J, Matoba N, Setoyama D, Watanabe D, Ohnishi Y, Yasui R, et al. The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Commun Biol. 2023;6:278.","journal-title":"Commun Biol"},{"key":"3922_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1113\/expphysiol.2010.055269","volume":"96","author":"LS Krivickas","year":"2011","unstructured":"Krivickas LS, Dorer DJ, Ochala J, Frontera WR. Relationship between force and size in human single muscle fibres. Exp Physiol. 2011;96:539\u201347.","journal-title":"Exp Physiol"},{"key":"3922_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/0092-8674(88)90463-1","volume":"52","author":"C Webster","year":"1988","unstructured":"Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell. 1988;52:503\u201313.","journal-title":"Cell"},{"key":"3922_CR45","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1152\/physrev.00031.2010","volume":"91","author":"S Schiaffino","year":"2011","unstructured":"Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev. 2011;91:1447\u2013531.","journal-title":"Physiol Rev"},{"key":"3922_CR46","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/wdev.230","volume":"5","author":"J Talbot","year":"2016","unstructured":"Talbot J, Maves L. Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for susceptibility and resistance to muscle disease. Wiley Interdiscip Rev Dev Biol. 2016;5:518\u201334.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"3922_CR47","doi-asserted-by":"publisher","first-page":"344","DOI":"10.12965\/jer.140171","volume":"10","author":"SJ Choi","year":"2014","unstructured":"Choi SJ. Differential susceptibility on myosin heavy chain isoform following eccentric-induced muscle damage. J Exerc Rehabil. 2014;10:344\u20138.","journal-title":"J Exerc Rehabil"},{"key":"3922_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1462","volume":"12","author":"K Mukund","year":"2020","unstructured":"Mukund K, Subramaniam S. Skeletal muscle: a review of molecular structure and function, in health and disease. Wiley Interdiscip Rev Syst Biol Med. 2020;12: e1462.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"3922_CR49","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/sctm.21-0054","volume":"10","author":"M Siemionow","year":"2021","unstructured":"Siemionow M, Langa P, Harasymczuk M, Cwykiel J, Sielewicz M, Smieszek J, et al. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle\u2019s function in Duchenne muscular dystrophy. Stem Cells Transl Med. 2021;10:1406\u201318.","journal-title":"Stem Cells Transl Med"},{"key":"3922_CR50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12015-017-9792-7","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow M, Cwykiel J, Heydemann A, Garcia-Martinez J, Siemionow K, Szilagyi E. Creation of dystrophin expressing chimeric cells of myoblast origin as a novel stem cell based therapy for Duchenne muscular dystrophy. Stem Cell Rev Rep. 2018;14:189\u201399.","journal-title":"Stem Cell Rev Rep"},{"key":"3922_CR51","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0892-0362(03)00073-4","volume":"25","author":"JP Maurissen","year":"2003","unstructured":"Maurissen JP, Marable BR, Andrus AK, Stebbins KE. Factors affecting grip strength testing. Neurotoxicol Teratol. 2003;25:543\u201353.","journal-title":"Neurotoxicol Teratol"},{"key":"3922_CR52","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.stem.2007.09.016","volume":"1","author":"R Benchaouir","year":"2007","unstructured":"Benchaouir R, Meregalli M, Farini A, D\u2019Antona G, Belicchi M, Goyenvalle A, et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell. 2007;1:646\u201357.","journal-title":"Cell Stem Cell"},{"key":"3922_CR53","doi-asserted-by":"publisher","first-page":"H1983","DOI":"10.1152\/ajpheart.00784.2010","volume":"300","author":"C Perrino","year":"2011","unstructured":"Perrino C, Gargiulo G, Pironti G, Franzone A, Scudiero L, De Laurentis M, et al. Cardiovascular effects of treadmill exercise in physiological and pathological preclinical settings. Am J Physiol Heart Circ Physiol. 2011;300:H1983\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3922_CR54","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/thoraxjnl-2022-218798","volume":"77","author":"DJ Birnkrant","year":"2022","unstructured":"Birnkrant DJ, Carter JC. Back to basics: the respiratory management of Duchenne muscular dystrophy. Thorax. 2022;77:743\u20134.","journal-title":"Thorax"},{"key":"3922_CR55","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mus.21544","volume":"41","author":"CM McDonald","year":"2010","unstructured":"McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41:500\u201310.","journal-title":"Muscle Nerve"},{"key":"3922_CR56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","volume":"8","author":"JW McGreevy","year":"2015","unstructured":"McGreevy JW, Hakim CH, McIntosh MA, Duan D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech. 2015;8:195\u2013213.","journal-title":"Dis Model Mech"},{"key":"3922_CR57","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2183\/pjab.67.148","volume":"67","author":"H Tanaka","year":"1991","unstructured":"Tanaka H, Hayashi K, Ozawa E. Positive immunostaining with dystrophin antibodies in mdx skeletal muscle. Proc Jpn Acad Ser B. 1991;67:148\u201352.","journal-title":"Proc Jpn Acad Ser B"},{"issue":"4","key":"3922_CR58","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/antiox10040558","volume":"10","author":"M Frinchi","year":"2021","unstructured":"Frinchi M, Morici G, Mud\u00f3 G, Bonsignore MR, Di Liberto V. Beneficial role of exercise in the modulation of mdx muscle plastic remodeling and oxidative stress. Antioxidants (Basel). 2021;10(4):558.","journal-title":"Antioxidants (Basel)"},{"key":"3922_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3233\/JND-150106","volume":"2","author":"J Hyzewicz","year":"2015","unstructured":"Hyzewicz J, Ruegg UT, Takeda S. Comparison of experimental protocols of physical exercise for mdx mice and duchenne muscular dystrophy patients. J Neuromuscul Dis. 2015;2:325\u201342.","journal-title":"J Neuromuscul Dis"},{"key":"3922_CR60","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.nmd.2022.02.011","volume":"32","author":"KJ Suetterlin","year":"2022","unstructured":"Suetterlin KJ, M\u00e4nnikk\u00f6 R, Matthews E, Greensmith L, Hanna MG, Bostock H, et al. Excitability properties of mouse and human skeletal muscle fibres compared by muscle velocity recovery cycles. Neuromuscul Disord. 2022;32:347\u201357.","journal-title":"Neuromuscul Disord"},{"key":"3922_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13395-020-00234-5","volume":"10","author":"T Incitti","year":"2020","unstructured":"Incitti T, Magli A, Jenkins A, Lin K, Yamamoto A, Perlingeiro RCR. Pluripotent stem cell-derived skeletal muscle fibers preferentially express myosin heavy-chain isoforms associated with slow and oxidative muscles. Skelet Muscle. 2020;10:17.","journal-title":"Skelet Muscle"},{"key":"3922_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112434","volume":"42","author":"T Yasuda","year":"2023","unstructured":"Yasuda T, Ishihara T, Ichimura A, Ishihara N. Mitochondrial dynamics define muscle fiber type by modulating cellular metabolic pathways. Cell Rep. 2023;42: 112434.","journal-title":"Cell Rep"},{"key":"3922_CR63","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/MCO.0b013e32833cc93d","volume":"13","author":"IR Lanza","year":"2010","unstructured":"Lanza IR, Nair KS. Mitochondrial metabolic function assessed in vivo and in vitro. Curr Opin Clin Nutr Metab Care. 2010;13:511\u20137.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"3922_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115763","volume":"9","author":"E Rybalka","year":"2014","unstructured":"Rybalka E, Timpani CA, Cooke MB, Williams AD, Hayes A. Defects in mitochondrial ATP synthesis in dystrophin-deficient mdx skeletal muscles may be caused by complex I insufficiency. PLoS ONE. 2014;9: e115763.","journal-title":"PLoS ONE"},{"key":"3922_CR65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/hmg\/dds415","volume":"22","author":"JM Percival","year":"2013","unstructured":"Percival JM, Siegel MP, Knowels G, Marcinek DJ. Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibition. Hum Mol Genet. 2013;22:153\u201367.","journal-title":"Hum Mol Genet"},{"key":"3922_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026963","volume":"6","author":"MP Siegel","year":"2011","unstructured":"Siegel MP, Kruse SE, Knowels G, Salmon A, Beyer R, Xie H, et al. Reduced coupling of oxidative phosphorylation in vivo precedes electron transport chain defects due to mild oxidative stress in mice. PLoS ONE. 2011;6: e26963.","journal-title":"PLoS ONE"},{"key":"3922_CR67","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.mehy.2015.08.015","volume":"85","author":"CA Timpani","year":"2015","unstructured":"Timpani CA, Hayes A, Rybalka E. Revisiting the dystrophin-ATP connection: how half a century of research still implicates mitochondrial dysfunction in Duchenne muscular dystrophy aetiology. Med Hypotheses. 2015;85:1021\u201333.","journal-title":"Med Hypotheses"},{"key":"3922_CR68","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1172\/JCI7866","volume":"104","author":"ER Barton-Davis","year":"1999","unstructured":"Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999;104:375\u201381.","journal-title":"J Clin Invest"},{"key":"3922_CR69","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","volume":"24","author":"C Godfrey","year":"2015","unstructured":"Godfrey C, Muses S, McClorey G, Wells KE, Coursindel T, Terry RL, et al. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum Mol Genet. 2015;24:4225\u201337.","journal-title":"Hum Mol Genet"},{"key":"3922_CR70","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/mt.2010.213","volume":"19","author":"PS Sharp","year":"2011","unstructured":"Sharp PS, Bye-a-Jee H, Wells DJ. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther. 2011;19:165\u201371.","journal-title":"Mol Ther"},{"key":"3922_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031937","volume":"7","author":"M van Putten","year":"2012","unstructured":"van Putten M, Hulsker M, Nadarajah VD, van Heiningen SH, van Huizen E, van Iterson M, et al. The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE. 2012;7: e31937.","journal-title":"PLoS ONE"},{"key":"3922_CR72","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/jnnp-2013-306350","volume":"85","author":"JC van den Bergen","year":"2014","unstructured":"van den Bergen JC, Wokke BH, Janson AA, van Duinen SG, Hulsker MA, Ginjaar HB, et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry. 2014;85:747\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3922_CR73","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s40478-023-01657-z","volume":"11","author":"N Cardone","year":"2023","unstructured":"Cardone N, Taglietti V, Baratto S, Kefi K, Periou B, Gitiaux C, et al. Myopathologic trajectory in Duchenne muscular dystrophy (DMD) reveals lack of regeneration due to senescence in satellite cells. Acta Neuropathol Commun. 2023;11:167.","journal-title":"Acta Neuropathol Commun"},{"key":"3922_CR74","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1242\/dev.129.12.2987","volume":"129","author":"MR Wada","year":"2002","unstructured":"Wada MR, Inagawa-Ogashiwa M, Shimizu S, Yasumoto S, Hashimoto N. Generation of different fates from multipotent muscle stem cells. Development. 2002;129:2987\u201395.","journal-title":"Development"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-024-03922-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-024-03922-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-024-03922-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:33:34Z","timestamp":1726738414000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-024-03922-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3922"],"URL":"https:\/\/doi.org\/10.1186\/s13287-024-03922-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3767279\/v1","asserted-by":"object"}]},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in compliance with the regulations of the Kyoto University Recombinant DNA Experiment Safety Committee and were approved by the Kyoto University Animal Experiment Committee (\u201cResearch on rehabilitation interventions to maximize the therapeutic effect of cell transplantation in a model of refractory muscle disease\u201d, No. 17-81, approved on March 17, 2017; \u201cExperiments to elucidate the pathogenesis mechanisms of DMD mouse model by applying ATP visualization technology\u201d, No. 20-141, approved on October 7, 2020) and by the Committee of Experimental Animal Research of National Cerebral and Cardiovascular Center (\u201cStudies on the dynamics of energy metabolism in mice and rats in vivo\u201d, 21053, 22029, 23018, approved on June 16, 2021). All animal models and experimental procedures conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Generation of human immortalized myoblasts Hu5\/KD3 was approved by the Ethics Committee of the National Center for Geriatrics and Gerontology (\u201cMolecular and Cellular Biological Analysis of Tissue repair and Regeneration\u201d, No. 09-01, approved in October, 2009), and was conducted from the human primary myoblasts obtained by biopsy from a 44-year-old woman with informed consent at the Kanagawa Cancer Center Research Institute as described by Wada et al. [\n                      \n                      ]. The Hu5\/KD3 cells were transferred to Kyoto University by Material Transfer Agreement (OUTBOUND QUICK-MATERIAL TRANSFER AGREEMENT, signed on February 7, 2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"313"}}